Table 1

Characteristics of studies included in systematic review and quantitative data synthesis

TrialYearStudy designFollow-up (weeks)GroupsNAge (yrs)Sex (M/F)Duration of diabetes (yrs)HbA1c at baseline (%)24-h BP at baseline (mmHg)CFB in 24-h BP (mmHg)
Lambers Heerspink et al. (11)2013Double-blind, parallel12Placebo2558.018/76.57.5131.0/74.0−0.7*
Dapa (10 mg/day)2453.716/86.57.7133.0/76.0−5.6*
HCTZ (25 mg/day)2654.815/116.07.4122.0/69.0−4.9*
Tikkanen et al. (12)2015Double-blind, parallel12Placebo27160.3168/103NA7.9131.7/75.20.48/0.32
Empa (10 mg/day)27660.6171/105NA7.9131.3/75.1−3.44/−1.04
Empa (25 mg/day)27659.9156/120NA7.9131.2/74.6−4.16/−1.72
Weber et al. (14)2015Double-blind, parallel12Placebo31156.2171/1407.68.0146.6/87.2−6.7/−5.5
Dapa (10 mg/day)30255.6179/1238.28.1145.9/87.0−9.6/−6.2
Amin et al. (9)2015Double-blind, parallel4Placebo3855.124/146.48.2136.1/81.9
Ertu (1 mg/day)3954.427/127.58.4133.1/78.7−2.97/−2.7**
Ertu (5 mg/day)3853.825/135.58.1135.1/80.2−4.0/−3.18**
Ertu (25 mg/day)3952.527/125.88.3135.6/80.4−3.69/−2.3**
HCTZ (12.5 mg/day)3956.528/118.28.2139.5/82.7−3.2/−2.23**
Townsend et al. (13)2016Double-blind, parallel6Placebo5659.633/23NA8.2136.7/78.4−1.2/−0.3
Cana (100 mg/day)5757.834/23NA8.1136.5/78−4.5/−2.2
Cana (300 mg/day)5658.331/25NA8.0139.6/79.3−6.2/−3.2
Weber et al. (15)2016Double-blind, parallel12Placebo22457.0129/957.38.0149.2*
Dapa (10 mg/day)22556.0118/1077.78.1146.5*−4.45**
Karg et al. (10)2018Double-blind, crossover6Placebo−0.5/0
Dapa (10 mg/day)5960.336/295.56.7129.0/77.0−3.0/−2.0
  • Cana, canagliflozin; Dapa, dapagliflozin; Empa, empagliflozin; Ertu, ertugliflozin; HCTZ, hydrochlorothiazide; F, female; M, male; NA, not available; yrs, years.

  • *Data on diastolic BP were not reported.

  • **Placebo-adjusted CFB is reported.